<DOC>
	<DOCNO>NCT02735603</DOCNO>
	<brief_summary>The purpose study evaluate potential effect naltrexone bupropion extended-release combination cardiac repolarization healthy participant .</brief_summary>
	<brief_title>Study Evaluate Effect Naltrexone Bupropion Extended-Release Combination Cardiac Repolarization Healthy Participants</brief_title>
	<detailed_description>The drug test study call naltrexone HCl/bupropion HCl ( NB ) . NB approve U.S. Food Drug Administration ( FDA ) addition reduced-calorie diet increase physical activity chronic weight management adult obese overweight least one additional weight-related condition high blood pressure , diabetes high cholesterol . This study conduct determine potential effect NB relative placebo cardiac repolarization . The study enroll approximately 84 participant . Participants randomly assign ( chance , like flip coin ) 1 6 treatment sequence , remain undisclosed participant study doctor study ( unless urgent medical need ) : - Naltrexone/Bupropion + Placebo + Moxifloxacin - Placebo + Moxifloxacin + Naltrexone/Bupropion - Moxifloxacin + Naltrexone/Bupropion + Placebo - Naltrexone/Bupropion + Moxifloxacin + Placebo - Placebo + Naltrexone/Bupropion + Moxifloxacin - Moxifloxacin + Placebo + Naltrexone/Bupropion This study consist 3 period separate washout period ( Days 11 25 ) . Participants admit clinic Day -2 ( Check-in ) study period remain confined clinic morning Day 12 study period . On Day -1 Day 11 period , participant undergo 24 hour Holter recording use ambulatory electrocardiograph recorder . This single center trial conduct United States . The overall time participate study approximately 96 day .</detailed_description>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Bupropion hydrochloride , naltrexone hydrochoride drug combination</mesh_term>
	<criteria>1 . Is healthy male female . 2 . Is age 18 55 year , inclusive , sign informed consent first dose study drug . 3 . Weighs least 50 kilogram ( kg ) body mass index ( BMI ) 18.0 35.0 kilogram per square meter ( kg/m^2 ) , inclusive , screen . 1 . Has know hypersensitivity moxifloxacin quinolone antibiotic component formulation naltrexone/bupropion . 2 . Has history seizure etiology , predisposition seizure . 3 . Has history significant cardiac disease . 4 . Has history bulimia . 5 . Has history anorexia nervosa . 6 . Has hemoglobin concentration less ( &lt; ) 12 gram per deciliter ( g/dL ) screen checkin ( day 2 ) period 1 . 7 . Has rest heart rate outside normal range 45 100 beat per minute screening checkin ( day 2 ) period 1 . 8 . Has orthostatic blood pressure great equal ( &gt; = ) 25 millimeter mercury ( mm Hg ) screen checkin ( day 2 ) period 1 . 9 . Has sustain supine systolic blood pressure &gt; =140 mm Hg &lt; =90 mm Hg diastolic blood pressure &gt; =90 mm Hg &lt; =50 mm Hg screening checkin ( day 2 ) period 1 . 10 . Has abnormal screening checkin ( day 2 ) period 1 ECG indicate second thirddegree atrioventricular block , 1 following : PR &gt; 220 msec , QRS &gt; 120 msec , QTcF &gt; 450 msec , rhythm sinus rhythm interpret investigator clinically significant could interfere accurate measurement QT interval . 11 . Has family history long QT syndrome . 12 . Had extensive exercising normal life , example , marathon running , triathlon , physical sport contest level .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>